Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.

DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

German biotech firm CureVac agreed to an alliance with drugmaker Bayer to get global support in seeking approval for the company’s experimental Covid-19 vaccine and for distribution, the daily Bild reported.

Moderna Inc.’s coronavirus vaccine mRNA-1273 became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering Covid-19 death toll of more than 307,000 lives lost.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

Ten Covid-19 vaccines could be available by the middle of 2021 if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said.

The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.

Envision Pharma Group, a leading global technology-enabled scientific communications company, announced the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.

Huntsworth, an international healthcare and communications group, announced an agreement to acquire Nucleus Global, one of the world’s largest medical specialist communications groups.

The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.